Insider buying last 90 days
No open-market insider purchases were filed for MRK in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MRK insider filing, plotted on the chart in Gekko.Open MRK in Gekko
Gekko Brief
Nov 4 closeMerck closed at $150.36 on 4 November 2026, +3.9% on the day. The price sits above both the 50-day ($146.54) and 200-day ($127.28) moving averages, inside a 52-week range of $82.01 to $156.92. The GekkoIndex reads 54.4, in the Neutral zone, down 7.1 points over five sessions. Gekko Fair Value is $164.44, so the price is 8.6% below it.
The next earnings report is due on 2 February 2027, 89 days away (before open). Over the last 8 reports the company beat the earnings estimate 8 times, with an average move of 3.8% across the report. Smart-money activity over the last 90 days includes 2 Congress purchases and 0 sales. Seasonally, the next 20 trading days from this point averaged +3.1% over the last 5 years, rising in 3 of them.
22 firms rate the stock: 15 buy, 7 hold and 0 sell, with a consensus target of $159.91. A typical daily move is about 3.3%, and a typical 20-day move about 4.3%. On the swing-trade checklist, 5 items read supportive and 0 read as a headwind.
A plain summary of the figures as of the Nov 4, 2026 close.
Merck price vs fair value
Close $150.36200-day averageGekko Fair Value $164.44
Merck quick facts
- Market cap
- $370.9B
- P/E ratio
- 149.9
- Forward P/E
- 16
- EPS, TTM
- $0.99
- Revenue, TTM
- $67.38B
- Profit margin
- 3.6%
- Dividend yield
- 2.25%
- Beta
- 0.12
- Volume
- 10.71M avg 10.37M
- 1-year return
- +82.3%
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±4.3%
- 50-day average
- $146.54
- 200-day average
- $127.28
- Next earnings
- Feb 2 before open
- Shares outstanding
- 2.47B
Merck swing-trade checklist
Merck scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive1 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $150.36 is above the 50-day ($146.54) and 200-day ($127.28) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
54.4, Neutral
Reading 54.4 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
8.6% below
Price is 8.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 2 buys / 0 sales.
See smart money - Earnings risksupportive
Reports in 89 days
Next report Feb 2, 2027, 89 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.1% on average
From this point in the calendar, the next 20 trading days averaged +3.1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Merck stock chart and price history
Merck closed at $150.36 on Nov 4, 2026, +82.3% over the past year, inside a 52-week range of $82.01 to $156.92.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +5.9%
- 3 months
- +17.1%
- 6 months
- +32.4%
- 1 year
- +82.3%
The full MRK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MRK in Gekko
Follow Merck through every session
Put MRK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MRK in GekkoFree for 7 days. No credit card required.
About Merck
Merck operates through two main businesses, Pharmaceuticals and Animal Health. The Pharmaceutical side develops medicines for people, addressing areas such as cancer, hospital care, immune conditions, neurological disorders, viral infections, heart disease, and diabetes, alongside vaccines given to children, teenagers, and adults. The Animal Health arm researches, makes, and sells veterinary medicines and vaccines, along with tools for identifying, tracking, and monitoring animal health.
Merck's medicines and vaccines reach the market through wholesalers, pharmacies, and hospitals, as well as government bodies and managed care groups such as HMOs and pharmacy benefit managers. Individual doctors and their distributors, veterinarians, and livestock producers also make up part of its customer base. The company works with other firms, including AstraZeneca, Bayer, Eisai, Ridgeback Biotherapeutics, and Gilead Sciences, on developing and bringing to market long-acting HIV treatments.
Merck traces its founding to 1891 and is headquartered in Kenilworth, New Jersey. Its shares are listed on the NYSE under the ticker MRK.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- merck.com
Merck GekkoIndex: the smart money zone
Merck’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.4, in the Neutral zone, down 7.1 points over five sessions.
54.4Neutral
Down 7.1 points over five sessions, from the Accumulation zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 45 | +0.1% | +1.7% | ||
| Accumulation | 213 | +0.7% | −0.2% | ||
| Neutral (current zone) | 379 | −0.1% | +1.1% | ||
| Distribution | 54 | +0.6% | +1.3% | ||
| Selling | 6 | Too few readings yet | |||
Average MRK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the MRK price, zone by zone.Track MRK in Gekko
Is Merck stock overvalued? Gekko Fair Value
Merck trades 8.6% below Gekko Fair Value of $164.44, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Merck shares are worth, recalculated every trading day.
$164.44
Gekko Fair Value, Nov 4, 2026
8.6% Undervalued
At the end of Aug 2026 the price was 8.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open MRK in Gekko
Merck insider and Congress trading
No open-market insider purchases were filed for Merck, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
2trades disclosed: 2 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Maria Elvira Salazar House, FL, purchase | $15,001 - $50,000 | Sep 10 traded Aug 19 |
| Ro Khanna House, CA, purchase | $15,001 - $50,000 | Sep 7 traded Aug 7 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Merck has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $757.0M
- As a share of market cap
- 0.20%
- Trailing four quarters
- $4.21B
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold MRK.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Merck earnings: next date and track record
Merck reports on Feb 2, 2027, before the open (89 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Feb 2, 2027
Expected before the open, 89 days away
- EPS estimate
- $1.77
- Revenue estimate
- $16.32B
8 of 8reports beat the EPS estimate
±3.8%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 29, 2026 AI summary
- What they said
- Merck reported Q3 2026 revenue of $18.1 billion, driven by new product launches, oncology strength, and animal health. Key milestones include positive Phase III data for sac-TMT in endometrial cancer from the TROFuse program, landmark Phase III results for cancer vaccine entismodigene in melanoma, and Phase 2b progress in immunology (TL1a/HS). Management emphasized pipeline de-risking and commercial execution as KEYTRUDA LOE approaches.
- Guidance
- Management expressed confidence in long-term growth beyond the KEYTRUDA loss-of-exclusivity period. Full-year 2026 outlook details to be provided by CFO Caroline Litchfield, with continued investment in launches and pipeline advancement prioritized.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $2.49 est $2.09 | $18.09B est $17.33B | +6.1% |
| Aug 4, 2026 | −$0.13 est −$0.26 | $16.61B est $16.37B | +0.4% |
| Apr 30, 2026 | −$1.28 est −$1.50 | $16.29B est $15.85B | +1.1% |
| Feb 3, 2026 | $2.04 est $2.01 | $16.40B est $16.20B | +4.4% |
| Oct 30, 2025 | $2.58 est $2.36 | $17.28B est $16.98B | −0.7% |
| Jul 29, 2025 | $2.13 est $2.03 | $15.81B est $15.86B | −2.7% |
| Apr 24, 2025 | $2.22 est $2.13 | $15.53B est $15.34B | +5.1% |
| Feb 4, 2025 | $1.72 est $1.67 | $15.62B est $15.48B | −10.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Merck stock forecast and analyst price targets
Analysts’ average 12-month price target for Merck is $159.91, +6.4% from the last close, from 22 firms rating the stock in the last 90 days.
$159.91consensus 12-month target, +6.4% from the last close
Now $150.36Avg $159.91
Low $105High $180
Each firm’s latest rating in the last 90 days: 22 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 3 | DZ BANK AG | $153 | +1.8% |
| Nov 2 | Leerink Partners | $162 | +7.7% |
| Nov 2 | Freedom Capital Markets | $140 | −6.9% |
| Nov 2 | Cantor Fitzgerald | $155 | +3.1% |
| Nov 1 | Cantor Fitzgerald | $155 | +3.1% |
+1.1%average 20-day move after past Neutral readings
+3.1%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Merck seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Merck averaged +3.1% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.6% | 1 of 5 |
| Next 10 trading days | +1.0% | 2 of 5 |
| Next 15 trading days | +4.0% | 2 of 5 |
| Next 20 trading days | +3.1% | 3 of 5 |
| Next 30 trading days | +2.6% | 3 of 5 |
For scale, MRK’s typical 20-trading-day move in either direction is about 4.3%.
Merck market cap and key statistics
Merck’s market cap is $370.9B, with a P/E ratio of 149.9 and revenue of $67.38B over the last twelve months.
Valuation
- Market cap
- $370.9B
- P/E ratio
- 149.9
- Forward P/E
- 16
- EPS, TTM
- $0.99
- Gekko Fair Value
- $164.44
Trading
- Volume
- 10.71M
- Avg volume, 20 days
- 10.37M
- 52-week high
- $156.92
- 52-week low
- $82.01
- Shares outstanding
- 2.47B
Financials
- Revenue, TTM
- $67.38B
- Profit margin
- 3.6%
- Return on equity
- 7%
- Quarterly earnings growth, YoY
- −12.0%
Risk and income
- Beta
- 0.12
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±4.3%
- Dividend yield
- 2.25%
Merck stock news this week
Coverage of Merck this week reads positive: 8 positive, 5 neutral and 6 negative headlines.
- Merck wins FDA nod for Bravecto in screwworm infestations (MRK)Seeking Alpha, Nov 4
- 8,663 Merck & Co., Inc. $MRK Shares Sold by Factory Mutual Insurance Co.MarketBeat, Nov 4
- AIA Group Ltd Sells 55,326 Shares of Merck & Co., Inc. $MRKMarketBeat, Nov 4
- Merck & Company, Inc. Stock 12‑Month Price Target Raised to $162.25, Implies 12% UpsideTradingView, Nov 4
- 6,400 Merck & Co., Inc. $MRK Shares Purchased by Aware Super Pty Ltd as trustee of Aware SuperDefense World, Nov 4
- Merck (MRK) grants director Paul J. Diaz 613.073 stock units payable entirely in cash.Stock Titan, Nov 4
Merck peers
Merck’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Distribution | 27.7% above |
| JNJJohnson & Johnson | Neutral | 1.7% below |
| ABBVAbbVie | Neutral | 26.5% above |
| AZNAstraZeneca | Distribution | 34.1% below |
| PFEPfizer | Neutral | 4.1% below |
| VRTXVertex Pharmaceuticals | Neutral | 16.8% above |
A peer links to its own page where one exists.
Merck stock FAQ
What is Merck’s market cap?
Merck’s market cap is $370.9B at the Nov 4, 2026 close of $150.36, with 2.47B shares outstanding. The shares trade on a P/E ratio of 149.9.
What is the Merck stock forecast?
The consensus analyst 12-month price target for Merck is $159.91, +6.4% from the last close. Of the 22 firms that rated the stock in the last 90 days, 15 rate it a buy, 7 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Merck stock overvalued or undervalued?
On Gekko’s estimate Merck is undervalued: the Nov 4, 2026 close of $150.36 is 8.6% below Gekko Fair Value of $164.44. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Merck report earnings next?
Merck is expected to report on Feb 2, 2027, before the market opens (89 days away). Analysts expect earnings of $1.77 per share on revenue of $16.32B. Merck beat the earnings estimate in 8 of its last 8 reports, moving 3.8% on average across the report.
What is Merck’s 52-week high and low?
Merck’s 52-week high is $156.92 and its 52-week low is $82.01; it closed at $150.36 on Nov 4, 2026, +82.3% over the past year.
Is Merck stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (trend, fair value, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Merck the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.